Oral, disease-modifying therapy
for diabetic neuropathy.
A preclinical programme, designed to act on the nerve damage.
Oral, disease-modifying therapy
Earthpharm Technologies
We discover and develop drugs
for diabetic neuropathy.
Diabetic neuropathy is driven by several interacting pathways: oxidative stress, mitochondrial failure, inflammation and glycation. First-line drugs act downstream, on the pain.
- In cells
- Five endpoints improved in human neuronal cells under high-glucose stress, in independent CRO studies: survival, neurite outgrowth, apoptosis, oxidative stress and mitochondrial membrane potential.
- Targets
- Computational screening maps our lead molecules, first identified in a botanical source, to eight upstream targets. Confirming them at the bench is part of the programme.
- Engine
- Earthpharm NPDE, our Natural Product Discovery Engine: mass spectrometry, target prediction and developability models, corrected for natural-product chemistry and trained on our own lab data. It mapped EP-001 to its eight targets, and it is built to find the programmes that follow.
Stage
Preclinical, TRL 3 to 4
Evidence
Independent CRO data in human neuronal cells
Not yet shown
Animal or human data
Recognition
DPIIT DIPP281541
Asset
New chemical entities, licensed to pharma
Platform
Earthpharm NPDE, built on our own lab data
Pipeline
Programme Indication Stage Route
EP-001 Diabetic neuropathy Preclinical, TRL 3 to 4 New chemical entities, global licensing
Discovery
Hundreds of compounds in one source,
most of them unidentified.
- Built: the workflow, and the eight-target panel behind EP-001.
- Being built: the natural-product correction layer and a scoring model trained on our own bench results.
- Owned: every data point is generated on our material, at our cost, by Earthpharm.
Identities are coded pending patent filings. Available under NDA.
Programme membership
and research affiliation
A member of the KSAP 2026 cohort at C-CAMP, working in affiliation with a central government research institute.
Programme membership
KSAP, 2026 cohort
Karnataka Startup Advancement Programme
Implemented by C-CAMP
Implementing institution for KSAP
C-CAMP
Centre for Cellular and Molecular Platforms
Bangalore Life Science Cluster, DBT, Government of India
Research affiliation
Central government research institute
Government of India
Open a conversation
For partnerships, investor relations and scientific collaboration
No approved drug modifies
diabetic neuropathy.
- 589 million adults live with diabetes worldwide, rising to 853 million by 2050
- 1 in 2 people with diabetes develop diabetic neuropathy over time
- 80% of lower-limb amputations in people with diabetes are preceded by a foot ulcer; neuropathy is the leading risk factor for those ulcers
- 0 approved disease-modifying therapies for diabetic neuropathy, per the American Diabetes Association
About 18.6 million people worldwide have a diabetic foot ulcer each year, and up to one in three people with diabetes will develop one in their lifetime. Five years after a major amputation, more than 70% of patients have died.
“There are currently no approved disease-modifying therapies for … diabetic neuropathy, and multiple clinical trials for these conditions have failed.”
How patients describe it
Burning, stabbing, tingling, numbness, pain from light touch, weakness.
Standard of care: pregabalin, gabapentin, duloxetine and tricyclic antidepressants. They treat the pain; dizziness and drowsiness limit their use; none changes the course of the nerve damage.
Sources IDF Diabetes Atlas, 11th edition, 2025 Feldman et al., Nature Reviews Disease Primers, 2019 Armstrong, Boulton and Bus, New England Journal of Medicine, 2017 Armstrong et al., JAMA, 2023 Pop-Busui et al., American Diabetes Association position statement, Diabetes Care, 2017
The Team
Founders and advisers
Founding team
Scientific execution
Advisers
Three decades of CMC development across novel chemical entities and generics. Previously Vice President of Pharmaceutical Development & Quality at vTv Therapeutics, where lead candidates were progressed through IND and Phases 1 to 3; earlier, General Manager of Research at Torrent Pharma. PhD in Chemistry & Biochemistry (drug-DNA interactions), Seton Hall University.
Chevening Scholar and graduate of Queen Mary University of London, specialised in Intellectual Property Law. Advises technology, healthcare and start-up clients on regulatory compliance, IP protection and contractual negotiation across IPR, medical law, and technology, media and telecommunications. Represents clients at the Supreme Court of India, multiple high courts, the National Green Tribunal and arbitral institutions.